Solve Your mAB Capture Scaling Challenges

Monoclonal antibodies (mAbs) are an extremely successful class of therapeutic agents for a wide range of diseases. Improving and scaling their production to be able to produce larger quantities more cost effectively is an important goal for the pharmaceutical industry. There are several hurdles to scaling a mAb production process which must be overcome.

These challenges are coupled with an industry trend towards orphan drugs and more personalized medicine: treatments are tailored for smaller patient groups, allowing to treat them with the right product. This leads to smaller antibody batch sizes, where flexible manufacturing options are required. This shift effectively allows production plants to become multiproduct facilities to increase the overall throughput of the facility, which opens new revenue streams and opportunities to amortize the plant more quickly.

To realize the opportunities provided by a multiproduct facility, new production solutions are required to accommodate all scales in a flexible way. This is partly linked to hardware and the way chromatography capture is performed.

Membrane chromatography technologies provide an exciting new path towards scalability with shorter cycle times and a smaller production footprint. Considering alternative technologies to those currently in use may be attractive, however their implementation requires very close alignment with PD and procurement.

Discover a membrane technology that is opening the door for full membrane-based processes that will revolutionize the industry.